 |
95 Diseases |  |
5 Trials |
|
5 Trials |  |
746 News |  |
| «12345678910 |
- Targretin oral (bexarotene oral) / ReXceptor
Enrollment closed, Metastases: GemBex: Gemcitabine and Bexarotene in Treating Patients With Progressive or Refractory Stage IB, Stage II, Stage III, or Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Mar 25, 2013
P2, N=84, Active, not recruiting, Sponsor: University College, London
Recruiting --> Active, not recruiting
- Targretin oral (bexarotene oral) / ReXceptor
Enrollment closed, Combination therapy: Intravenous (IV) Decitabine and Oral Bexarotene for Acute Myelogenous Leukemia (AML) (clinicaltrials.gov) - Feb 28, 2013
P1, N=19, Active, not recruiting, Sponsor: Washington University School of Medicine
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Targretin oral (bexarotene oral) / ReXceptor
New P2 trial: BEAT-AD: Bexarotene Amyloid Treatment for Alzheimer's Disease (clinicaltrials.gov) - Jan 31, 2013
P2, N=20, Active, not recruiting, Sponsor: The Cleveland Clinic
- |||||| Adcetris (brentuximab vedotin) / Takeda, Pfizer
Enrollment open: A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study) (clinicaltrials.gov) - Jan 6, 2013
P3, N=124, Recruiting, Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting Ongoing --> Recruiting
- Zolinza (vorinostat) / Merck (MSD), Targretin oral (bexarotene oral) / ReXceptor
Enrollment change: Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma (clinicaltrials.gov) - Oct 2, 2012
P2, N=40, Recruiting, Sponsor: University of Washington
Ongoing --> Recruiting N=60 --> 40
- | Targretin oral (bexarotene oral) / ReXceptor
Trial completion: Bexarotene Augmentation of Antipsychotic Treatment for Chronic Schizophrenia (clinicaltrials.gov) - Jul 24, 2012
P3, N=90, Completed, Sponsor: Beersheva Mental Health Center
N=60 --> 40 Recruiting --> Completed
- | HuMax-CD4 (zanolimumab) / Emergent Biosolutions
Trial termination: Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome (clinicaltrials.gov) - Jul 23, 2012
P3, N=76, Terminated, Sponsor: Emergent Product Development Seattle LLC
Recruiting --> Completed Recruiting --> Terminated; New sponsor, other treatments available
- Zolinza (vorinostat) / Merck (MSD), Targretin oral (bexarotene oral) / ReXceptor
Enrollment open: Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma (clinicaltrials.gov) - Jul 17, 2012
P2, N=40, Recruiting, Sponsor: University of Washington
Recruiting --> Terminated; New sponsor, other treatments available Suspended --> Recruiting
- Targretin oral (bexarotene oral) / ReXceptor
Trial termination: Ultraviolet Light Therapy Using Methoxsalen With or Without Bexarotene in Treating Patients With Mycosis Fungoides (clinicaltrials.gov) - Jun 18, 2012
P3, N=93, Terminated, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Suspended --> Recruiting Active, not recruiting --> Terminated; poor accrual
- Targretin oral (bexarotene oral) / ReXceptor
Enrollment change: Ultraviolet Light Therapy Using Methoxsalen With or Without Bexarotene in Treating Patients With Mycosis Fungoides (clinicaltrials.gov) - Jun 18, 2012
P3, N=93, Terminated, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Terminated; poor accrual N=145 --> 93
- |||||||||| Adcetris (brentuximab vedotin) / Takeda, Pfizer
New P3 trial: A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study) (clinicaltrials.gov) - Apr 15, 2012
P3, N=124, Recruiting, Sponsor: Millennium Pharmaceuticals, Inc.
- Targretin oral (bexarotene oral) / ReXceptor
New P4 trial: TgBEX: Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene of Cutaneous T Cell Lymphoma (clinicaltrials.gov) - Apr 1, 2012
P4, N=15, Recruiting, Sponsor: Rennes University Hospital
- | Targretin oral (bexarotene oral) / ReXceptor, efatutazone (CS-7017) / Daiichi Sankyo
New P1 trial: Phase I Study of CS-7017 and Bexarotene (clinicaltrials.gov) - Jan 3, 2012
P1, N=22, Recruiting, Sponsor: Georgetown University
- Folotyn (pralatrexate) / Aurobindo
Enrollment change: Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma (clinicaltrials.gov) - Nov 22, 2011
P1, N=42, Active, not recruiting, Sponsor: Spectrum Pharmaceuticals, Inc
N=145 --> 93 N=22 --> 42
- Targretin oral (bexarotene oral) / ReXceptor, Leukine (sargramostim) / Partner Therap
Enrollment closed: Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia (clinicaltrials.gov) - Aug 23, 2011
P2, N=26, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
N=22 --> 42 Recruiting --> Active, not recruiting